Current status of potential therapeutic candidates for the COVID-19 crisis.
Identifieur interne : 001449 ( Main/Exploration ); précédent : 001448; suivant : 001450Current status of potential therapeutic candidates for the COVID-19 crisis.
Auteurs : Jiancheng Zhang [République populaire de Chine] ; Bing Xie [République populaire de Chine] ; Kenji Hashimoto [Japon]Source :
- Brain, behavior, and immunity [ 1090-2139 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-inflammatoires non stéroïdiens (usage thérapeutique), Anticoagulants (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Bévacizumab (usage thérapeutique), Cellules tueuses naturelles (MeSH), Chloroquine (usage thérapeutique), Facteurs immunologiques (usage thérapeutique), Glycoprotéine de spicule des coronavirus (MeSH), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Immunoglobulines par voie veineuse (usage thérapeutique), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (thérapie), Infections à coronavirus (traitement médicamenteux), Inhibiteurs des Janus kinases (usage thérapeutique), Interférons (usage thérapeutique), Monoxyde d'azote (usage thérapeutique), Médecine traditionnelle chinoise (MeSH), Oligoéléments (usage thérapeutique), Pandémies (MeSH), Peptidyl-Dipeptidase A (MeSH), Pneumopathie virale (thérapie), Transplantation de cellules souches mésenchymateuses (MeSH), Vaccins antiviraux (usage thérapeutique), Vitamines (usage thérapeutique), Zinc (usage thérapeutique).
- MESH :
- prévention et contrôle : Infections à coronavirus.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Anti-inflammatoires non stéroïdiens, Anticoagulants, Anticorps monoclonaux humanisés, Antipaludiques, Antiviraux, Bévacizumab, Chloroquine, Facteurs immunologiques, Hormones corticosurrénaliennes, Hydroxychloroquine, Immunoglobulines par voie veineuse, Inhibiteurs des Janus kinases, Interférons, Monoxyde d'azote, Oligoéléments, Vaccins antiviraux, Vitamines, Zinc.
- Betacoronavirus, Cellules tueuses naturelles, Glycoprotéine de spicule des coronavirus, Humains, Immunisation passive, Médecine traditionnelle chinoise, Pandémies, Peptidyl-Dipeptidase A, Transplantation de cellules souches mésenchymateuses.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Angiotensin-Converting Enzyme 2 (MeSH), Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Anticoagulants (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), Bevacizumab (therapeutic use), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunologic Factors (therapeutic use), Interferons (therapeutic use), Janus Kinase Inhibitors (therapeutic use), Killer Cells, Natural (MeSH), Medicine, Chinese Traditional (MeSH), Mesenchymal Stem Cell Transplantation (MeSH), Nitric Oxide (therapeutic use), Pandemics (MeSH), Peptidyl-Dipeptidase A (MeSH), Pneumonia, Viral (therapy), SARS-CoV-2 (MeSH), Spike Glycoprotein, Coronavirus (MeSH), Trace Elements (therapeutic use), Viral Vaccines (therapeutic use), Vitamins (therapeutic use), Zinc (therapeutic use).
- MESH :
- chemical , therapeutic use : Adrenal Cortex Hormones, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Humanized, Anticoagulants, Antimalarials, Antiviral Agents, Bevacizumab, Chloroquine, Hydroxychloroquine, Immunoglobulins, Intravenous, Immunologic Factors, Interferons, Janus Kinase Inhibitors, Nitric Oxide, Trace Elements, Viral Vaccines, Vitamins, Zinc.
- chemical : Angiotensin-Converting Enzyme 2, COVID-19 Vaccines, Peptidyl-Dipeptidase A, Spike Glycoprotein, Coronavirus.
- drug therapy : Coronavirus Infections.
- prevention & control : Coronavirus Infections.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Immunization, Passive, Killer Cells, Natural, Medicine, Chinese Traditional, Mesenchymal Stem Cell Transplantation, Pandemics, SARS-CoV-2.
Abstract
As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.
DOI: 10.1016/j.bbi.2020.04.046
PubMed: 32334062
PubMed Central: PMC7175848
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current status of potential therapeutic candidates for the COVID-19 crisis.</title>
<author><name sortKey="Zhang, Jiancheng" sort="Zhang, Jiancheng" uniqKey="Zhang J" first="Jiancheng" last="Zhang">Jiancheng Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xie, Bing" sort="Xie, Bing" uniqKey="Xie B" first="Bing" last="Xie">Bing Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Kenji" sort="Hashimoto, Kenji" uniqKey="Hashimoto K" first="Kenji" last="Hashimoto">Kenji Hashimoto</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. Electronic address: hashimoto@faculty.chiba-u.jp.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670</wicri:regionArea>
<wicri:noRegion>Chiba 260-8670</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32334062</idno>
<idno type="pmid">32334062</idno>
<idno type="doi">10.1016/j.bbi.2020.04.046</idno>
<idno type="pmc">PMC7175848</idno>
<idno type="wicri:Area/Main/Corpus">001882</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001882</idno>
<idno type="wicri:Area/Main/Curation">001882</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001882</idno>
<idno type="wicri:Area/Main/Exploration">001882</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Current status of potential therapeutic candidates for the COVID-19 crisis.</title>
<author><name sortKey="Zhang, Jiancheng" sort="Zhang, Jiancheng" uniqKey="Zhang J" first="Jiancheng" last="Zhang">Jiancheng Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xie, Bing" sort="Xie, Bing" uniqKey="Xie B" first="Bing" last="Xie">Bing Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Kenji" sort="Hashimoto, Kenji" uniqKey="Hashimoto K" first="Kenji" last="Hashimoto">Kenji Hashimoto</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. Electronic address: hashimoto@faculty.chiba-u.jp.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670</wicri:regionArea>
<wicri:noRegion>Chiba 260-8670</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Brain, behavior, and immunity</title>
<idno type="eISSN">1090-2139</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Anticoagulants (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Bevacizumab (therapeutic use)</term>
<term>COVID-19 (MeSH)</term>
<term>COVID-19 Vaccines (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunization, Passive (MeSH)</term>
<term>Immunoglobulins, Intravenous (therapeutic use)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Interferons (therapeutic use)</term>
<term>Janus Kinase Inhibitors (therapeutic use)</term>
<term>Killer Cells, Natural (MeSH)</term>
<term>Medicine, Chinese Traditional (MeSH)</term>
<term>Mesenchymal Stem Cell Transplantation (MeSH)</term>
<term>Nitric Oxide (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (MeSH)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Spike Glycoprotein, Coronavirus (MeSH)</term>
<term>Trace Elements (therapeutic use)</term>
<term>Viral Vaccines (therapeutic use)</term>
<term>Vitamins (therapeutic use)</term>
<term>Zinc (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens (usage thérapeutique)</term>
<term>Anticoagulants (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Bévacizumab (usage thérapeutique)</term>
<term>Cellules tueuses naturelles (MeSH)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Glycoprotéine de spicule des coronavirus (MeSH)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunisation passive (MeSH)</term>
<term>Immunoglobulines par voie veineuse (usage thérapeutique)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Inhibiteurs des Janus kinases (usage thérapeutique)</term>
<term>Interférons (usage thérapeutique)</term>
<term>Monoxyde d'azote (usage thérapeutique)</term>
<term>Médecine traditionnelle chinoise (MeSH)</term>
<term>Oligoéléments (usage thérapeutique)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (MeSH)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Transplantation de cellules souches mésenchymateuses (MeSH)</term>
<term>Vaccins antiviraux (usage thérapeutique)</term>
<term>Vitamines (usage thérapeutique)</term>
<term>Zinc (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term>
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Anticoagulants</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Bevacizumab</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulins, Intravenous</term>
<term>Immunologic Factors</term>
<term>Interferons</term>
<term>Janus Kinase Inhibitors</term>
<term>Nitric Oxide</term>
<term>Trace Elements</term>
<term>Viral Vaccines</term>
<term>Vitamins</term>
<term>Zinc</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin-Converting Enzyme 2</term>
<term>COVID-19 Vaccines</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens</term>
<term>Anticoagulants</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Bévacizumab</term>
<term>Chloroquine</term>
<term>Facteurs immunologiques</term>
<term>Hormones corticosurrénaliennes</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulines par voie veineuse</term>
<term>Inhibiteurs des Janus kinases</term>
<term>Interférons</term>
<term>Monoxyde d'azote</term>
<term>Oligoéléments</term>
<term>Vaccins antiviraux</term>
<term>Vitamines</term>
<term>Zinc</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Immunization, Passive</term>
<term>Killer Cells, Natural</term>
<term>Medicine, Chinese Traditional</term>
<term>Mesenchymal Stem Cell Transplantation</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Cellules tueuses naturelles</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Immunisation passive</term>
<term>Médecine traditionnelle chinoise</term>
<term>Pandémies</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Transplantation de cellules souches mésenchymateuses</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32334062</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2139</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>87</Volume>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Brain, behavior, and immunity</Title>
<ISOAbbreviation>Brain Behav Immun</ISOAbbreviation>
</Journal>
<ArticleTitle>Current status of potential therapeutic candidates for the COVID-19 crisis.</ArticleTitle>
<Pagination><MedlinePgn>59-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0889-1591(20)30589-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbi.2020.04.046</ELocationID>
<Abstract><AbstractText>As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Jiancheng</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Bing</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hashimoto</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan. Electronic address: hashimoto@faculty.chiba-u.jp.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Brain Behav Immun</MedlineTA>
<NlmUniqueID>8800478</NlmUniqueID>
<ISSNLinking>0889-1591</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014131">Trace Elements</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014815">Vitamins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber>
<NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9008-11-1</RegistryNumber>
<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber>
<NameOfSubstance UI="D015032">Zinc</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>NU90V55F8I</RegistryNumber>
<NameOfSubstance UI="C000592401">sarilumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014131" MajorTopicYN="N">Trace Elements</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ACE2 blocker</Keyword>
<Keyword MajorTopicYN="Y">Antimalaria</Keyword>
<Keyword MajorTopicYN="Y">Antiviral: Chinese traditional medicine</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Immunoenhancer</Keyword>
<Keyword MajorTopicYN="Y">Monoclonal antibody</Keyword>
<Keyword MajorTopicYN="Y">Vaccine</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32334062</ArticleId>
<ArticleId IdType="pii">S0889-1591(20)30589-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbi.2020.04.046</ArticleId>
<ArticleId IdType="pmc">PMC7175848</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
<li>République populaire de Chine</li>
</country>
<region><li>Hubei</li>
</region>
<settlement><li>Wuhan</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><region name="Hubei"><name sortKey="Zhang, Jiancheng" sort="Zhang, Jiancheng" uniqKey="Zhang J" first="Jiancheng" last="Zhang">Jiancheng Zhang</name>
</region>
<name sortKey="Xie, Bing" sort="Xie, Bing" uniqKey="Xie B" first="Bing" last="Xie">Bing Xie</name>
</country>
<country name="Japon"><noRegion><name sortKey="Hashimoto, Kenji" sort="Hashimoto, Kenji" uniqKey="Hashimoto K" first="Kenji" last="Hashimoto">Kenji Hashimoto</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32334062 |texte= Current status of potential therapeutic candidates for the COVID-19 crisis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32334062" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |